 |
A
call for sponsorship to support the running and future development
of Glycosmedia |
| |
Click on the above headline for an overview
of the Glycosmedia diabetes news service and our call for sponsorship.
Brief details on how sponsorship will work can be seen here. For further details please contact (Jim Young, Editor-in-Chief) |
| |
|
|
Repeat
Dosing Data for Capsulin Phase II in type 2 diabetes presented
at the EASD Conference in Rome |
| |
Diabetology Limited, announced results from
the 10-day repeat-dosing of Capsulin™ oral insulin in patients with type 2 diabetes at the European Association for
the Study of Diabetes (EASD) meeting in Rome (Diabetology) |
| |
|
|
Oral
GLP-1 Study Presented at the EASD Conference in Rome |
| |
Results from a preclinical study on Axcess™ oral
formulated GLP-1 analogues have been presented in a poster presentation
during the European Association for the Study of Diabetes (EASD)
meeting in Rome (Diabetology) |
| |
|
|
New
diabetes rate up 90 percent in past decade |
| |
The rate of new cases of diabetes soared by
about 90 percent in the United States in the past decade, fueled
by growing obesity and sedentary lifestyles (Reuters) |
| |
|
|
Effects
of pioglitazone? on major cardiovascular adverse events in high
risk patients with type 2 diabetes |
| |
The PROactive study failed to show a significant
benefit for pioglitazone compared with placebo in people who had
type 2 diabetes as well as other evidence of cardiovascular disease.
Despite a re-analysis of secondary endpoint data from this study,
claims of this showing a significant benefit for pioglitazone appear
unjustified (National Prescribing Centre, UK) |
| |
|
|
GAD
Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes |
| |
GAD-alum may contribute to the preservation
of residual insulin secretion in patients with recent-onset type
1 diabetes, although it did not change the insulin requirement
( NeJM ) |
| |
|
|
Study
Finds Preventative Diabetes Care Reduces Amputation Occurrence |
| |
The APMA study, conducted by an independent
research firm, found that 25 percent of the 600 people surveyed
who had suffered an amputation from diabetes said they should have
seen a specialist - such as a podiatrist - sooner (Market Watch) |
| |
|
|
Drug
may prevent diabetes in arthritis patients |
| |
The risk of developing diabetes is cut in half
among rheumatoid arthritis patients who use hydroxychloroquine
for treatment, according to research findings reported this week
at the American College of Rheumatology Annual Scientific Meeting
in San Francisco (MedlinePlus) |
| |
|
|
Growing
Number of Consumers Trust Online Resources Over Other Media for
Researching Drug Treatment Information |
| |
60 percent would sign up for enewsletters -
25 percent would join email groups (PharmaLive) |
| |
|
|
Amylin
says Byetta outperformed Januvia in trial |
| |
Eli Lilly and Co and Amylin Pharmaceuticals
Inc said on Tuesday that a trial of their diabetes drug Byetta,
which was recently linked with six deaths from pancreatitis, reduced
glucose levels more than a rival drug from Merck & Co (BD Diabetes) |
| |
|
|
Tests
show 2-year benefits of Merck diabetes drug |
| |
Merck & Co's diabetes drug Januvia
substantially improves blood sugar levels over two years of treatment
when combined with the older drug metformin and is generally well
tolerated, new data on Tuesday showed (BD Diabetes) |
| |
|
|
Phenomix
and Forest Laboratories to Collaborate on Development and Commercialization
of Dutogliptin in Diabetes |
| |
Laboratories, Inc. and Phenomix Corporation
today announced that they have entered into a definitive collaboration
agreement to develop and commercialize dutogliptin (PHX1149) in
North America. Dutogliptin is Phenomix' proprietary orally administered,
small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently
undergoing Phase 3 clinical development in Type 2 diabetes mellitus
(PharmaLive) |
| |
|
|
Lilly
Announces Launch of Color Differentiation System for Humalog
and Humulin U-100 Insulin Products in the United States |
| |
With color differentiation, the redesigned labeling
can help patients, health care providers and pharmacists accurately
identify the insulin that has been prescribed (PharmaLive) |
| |
|
|
Sources
of funding |
| |
If you know of any sources of funding that we
can contact to support the running and future development of Glycosmedia
then please mail Jim Young, Editor-in-Chief jim@glycosmedia.com |
| |
|
